|
PipelineHermo Pharma Ltd. has an R&D pipeline consisting of two highly innovative programs. We aim to develop novel therapeutic approaches for unmet medical needs in the fields of neurology and neuro-ophthalmology. Currently, our most advanced product is HER-801, which is being developed for treatment of amblyopia in adults. Our proprietary neurotrophic factor CDNF is in late preclinical development with an aim to start first human studies in Parkinson's disease in 2014.
|
